-
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Thursday, January 23, 2025 - 4:02pm | 506Read More...On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01. The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion. Operational...
-
Intuitive Surgical Posts Q3 Earnings Beat, These Analysts Raise Forecasts On DV5 Uptake
Friday, October 18, 2024 - 12:19pm | 768Read More...Intuitive Surgical, Inc. (NASDAQ:ISRG) Thursday reported upbeat earnings for its third quarter. The company reported its results amid an exciting earnings season. Here are some key analyst takeaways. RBC Capital Markets analyst Shagun Singh reiterated an Outperform rating, while raising the price...
-
Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts
Friday, July 19, 2019 - 10:23am | 927Read More...Robotic surgical system manufacturer Intuitive Surgical, Inc. (NASDAQ: ISRG) reported above-consensus second-quarter results Thursday. The Analysts Canaccord Genuity analyst Jason Mills maintained a Buy rating on Intuitive Surgical and lifted the price target from $575 to $610. Stifel...
-
LivaNova Valuation Multiples Likely to Increase Amid Steady Progress, Stifel Says In Bullish Initiation
Friday, June 8, 2018 - 10:41am | 387Read More...The transformation medical device manufacturer LivaNova PLC (NASDAQ: LIVN) has undergone over the past 18 months has left a Stifel analyst impressed. The Analyst Analyst Rick Wise initiated coverage of LivaNova with a Buy rating and $115 price target. The Thesis LivaNova, formed...
-
LeMaitre Vascular's Lack Of Near-Term Catalysts Pushes Stifel To The Sidelines
Thursday, April 26, 2018 - 3:00pm | 325Read More...LeMaitre Vascular Inc (NASDAQ: LMAT) reported Q1 results, which led to a 14.6 percetn sell-off. The Analyst Stifel analyst Rick Wise downgraded LeMaitre from Buy to Hold and reduced his price target from $40 to $34. The Thesis Although LeMaitre's management remained steadfast and...
-
Zimmer Biomet Shares Are Better Positioned To Outperform; Stifel Upgrades
Wednesday, January 31, 2018 - 4:50pm | 381Read More...With a new and highly-experienced CEO at the helm, medical device maker Zimmer Biomet Holdings Inc (NYSE: ZBH) can gradually stabilize and, over time re-accelerate growth, an analyst at Stifel said. The Analyst Stifel analyst Rick Wise upgraded shares of Zimmer Biomet from Hold to Buy, and...
-
OrthoPediatrics Could Win By Tapping A Massive, Underserved Market, Says Stifel
Monday, November 6, 2017 - 3:43pm | 377Read More...Orthopediatrics Corp (NASDAQ: KIDS) is poised to achieve strong top-line growth due to its exclusive focus on the sizeable and largely underserved $2.5 billion pediatric orthopedic market, according to Stifel. Stifel initiated coverage of Orthopediatrics with a Buy rating and a $23 price...
-
How Surgeons Are Responding To TransEnterix's Senhance Following FDA Approval
Monday, October 30, 2017 - 10:40am | 545Read More...Transenterix Inc (NYSE: TRXC) investors were thrilled when the company’s Senhance system secured the first U.S. approval for abdominal surgical robotics in nearly two decades. And as Stifel Nicolaus found, excitement wasn’t exclusive to shareholders. “Surgeon interest in Senhance...
-
FDA Approval For Endologix's Nellix Likely Pushed To At Least 2020
Thursday, May 18, 2017 - 11:58am | 337Read More...Following the announcement by Endologix, Inc. (NASDAQ: ELGX) that it will no longer seek approval of the Nellix first generation device following a FDA meeting, Stifel said the potential U.S. approval is pushed to at least 2020 from the previous timeline of early-2018. The company would now...
-
UPDATE: Stifel Reiterates On TriVascular Technologies Following 3Q14 Sales Results
Tuesday, November 11, 2014 - 9:13am | 108Read More...In a report published Tuesday, Stifel analyst Rick Wise reiterated a Buy rating on TriVascular Technologies Inc (NASDAQ: TRIV), and raised the price target from $17.00 to $19.00. In the report, Stifel noted, “At $7.9M, TRIV 3Q14 sales rose 43% y/y and came in roughly in-line with consensus, but...
-
Stifel Lays Out The Bull Case For Intuitive Surgical
Wednesday, July 23, 2014 - 9:13am | 264Read More...Stifel analyst Rick Wise released a note upgrading Intuitive Surgical (NASDAQ: ISRG) from Hold to Buy and assigned a price target of $600. Wise believes that “the next leg of the ISRG story is starting to take shape” in response to the company’s recently released earnings...
-
UPDATE: Stifel Initiates Coverage On LeMaitre Vascular On Good Investment Opportunity
Tuesday, June 24, 2014 - 8:36am | 119Read More...In a report published Tuesday, Stifel analyst Rick Wise initiated coverage on LeMaitre Vascular (NASDAQ: LMAT) with a Buy rating and $11.00 price target. In the report, Stifel noted, “We are initiating coverage of LeMaitre Vascular, Inc. (LMAT) with a Buy rating and $11 target price, reflecting a 2...
-
UPDATE: Stifel Initiates Coverage on Tandem Diabetes Care on Multiple Growth Drivers
Monday, December 9, 2013 - 11:20am | 167Read More...In a report published Monday, Stifel analyst Rick Wise initiated coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Buy rating and $30.00 price target. In the report, Stifel noted, “We are initiating coverage with a Buy rating on the shares and a $30 target price. Tandem appears poised for...
-
UPDATE: Stifel Nicolaus Initiates Endologix at Buy on Compelling Growth
Friday, July 12, 2013 - 9:08am | 185Read More...In a report published Friday, Stifel Nicolaus analyst Rick Wise initiated coverage on Endologix (NASDAQ: ELGX) with a Buy rating and $18.00 price target. In the report, Stifel Nicolaus noted, “We are initiating coverage of Endologix, Inc. (ELGX) with a Buy rating and $18 target price. ELGX is...
-
Medtronic, Inc. (MDT) Maintains Market Perform Rating
Monday, March 22, 2010 - 9:52am | 139Read More...Analysts Rick Wise and Danielle Antalffy at Leerink Swann have released an update on Medtronic, Inc. (NYSE: MDT). On Friday, Medtronic’s REVO MRI-Safe Pacing System was recommended for approval with conditions by a FDA panel. Analysts believe that this outcome was largely expected. According to...
